Atyr Pharma, Inc. — 2015 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2015. The company is a clinical-stage biotechnology business developing Physiocrine-based therapeutics for severe, rare diseases. It reported no product-sales revenue. Financial statements were audited by Ernst & Young LLP, which issued an unqualified opinion; the auditor did not opine on internal control over financial reporting.
Financial performance and position
| Metric | 2015 | 2014 |
|---|---|---|
| Revenue | No product-sales revenue | No product-sales revenue |
| Research and development expense | $34.5 million | $16.8 million |
| General and administrative expense | $13.1 million | $6.8 million |
| Total operating expenses / operating loss | $47.6 million | $23.6 million |
| Net loss | $48.0 million | $24.4 million |
| Net loss per share, basic and diluted | $3.03 | $29.69 |
| Cash, cash equivalents and investments | $125.3 million | $15.9 million |
| Working capital | $85.8 million | $6.4 million |
| Commercial bank debt, net | $5.2 million | $8.4 million |
- Operating cash outflow was $36.8 million, compared with $22.8 million in 2014. Investing cash outflow was $72.0 million, primarily reflecting purchases of investment securities; financing cash inflow was $147.9 million.
- At year-end, cash was $53.0 million, with $42.5 million of short-term and $29.8 million of long-term investments. Management stated that available cash and investments were expected to fund current operations for at least 12 months.
- Debt is under a Silicon Valley Bank facility, bears fixed interest, is secured by company assets other than intellectual property, and matures in June 2017. Contractual bank debt payments, including interest and the final payment, totaled $5.9 million as of year-end. The company also had $0.8 million of operating lease commitments through May 2017.
- Margins are not meaningful because the company had no product revenue. The company had an accumulated deficit of $158.1 million and expected continued losses and increasing expenses.
Material changes and business developments
- Net loss nearly doubled year over year. R&D expense rose by $17.7 million, mainly from Resolaris manufacturing and clinical-development activities, higher R&D staffing costs, and a $1.4 million stock issuance to The Scripps Research Institute. G&A increased by $6.3 million, primarily from personnel, public-company costs, and intellectual-property work.
- The May 2015 IPO raised approximately $75.9 million net. A separate Series E preferred-stock financing generated approximately $75.6 million net; preferred stock converted into common stock at the IPO.
- In 2015, the company initiated Resolaris studies in early-onset FSHD, adult FSHD or LGMD2B, and a long-term adult-FSHD extension study. It selected iMod.Fc as a second development candidate for potential rare pulmonary diseases with an immune component; it remained preclinical, with manufacturing process development underway.
- Quarterly operating expenses rose during 2015, reaching $16.5 million in Q4; Q4 net loss was $16.5 million.
Outlook, risks and unusual items
- Management gave no specific revenue, earnings, or clinical milestone guidance. It expected continued substantial R&D and operating costs, further clinical development spending, and a need for additional capital to complete later-stage trials and potential commercialization.
- Resolaris remained in early clinical development; no pivotal trials had begun. Adult FSHD Phase 1b/2 results were exploratory and the study was not powered to establish efficacy. In a small 3.0 mg/kg cohort, the INQoL patient-reported measure suggested improvement at three months, but manual muscle testing showed little change and exploratory MRI and circulating markers showed no substantial treatment-placebo differences.
- Safety and immunogenicity require close attention. The filing reports low-titer anti-drug antibodies and generalized infusion-related reactions in Resolaris studies. One reaction in the adult FSHD study was reclassified as serious by the company; two patients in the extension study discontinued after reversible reactions. Mitigation procedures included reducing concentration and infusion rate, but effectiveness was not assured.
- The FDA had lifted a full clinical hold on the U.S. adult FSHD study but maintained a partial hold on Resolaris doses above 3.0 mg/kg, citing unresolved questions about deaths at high doses in rodent safety studies. The company was preparing additional information for the FDA.
- Other principal risks include slow enrollment in the early-onset FSHD study, uncertain clinical efficacy and regulatory pathways, reliance on third-party manufacturers and CROs, manufacturing scale-up and comparability, potential dilution or financing constraints, and dependence on intellectual-property protection. The company disclosed an unresolved trademark objection from Alexion concerning the Resolaris name. It reported no material legal proceedings.
Important facts for investors to verify
- Current status of the FDA partial clinical hold, dose plans, and any subsequent safety findings, including infusion reactions and anti-drug antibodies.
- Enrollment, retention, and results in the ongoing FSHD and LGMD2B trials; distinguish exploratory signals from evidence of clinically meaningful efficacy.
- Cash burn, investment liquidity, and whether management’s stated operating runway remains adequate as trial and manufacturing costs increase.
- Resolaris manufacturing scale-up, process comparability, supply capacity, and the costs and timing of Fujifilm’s work and other contract manufacturing arrangements.
- Progress from iMod.Fc preclinical candidate selection to IND-enabling work and clinical testing, and the strength and scope of the company’s patent and trademark positions.